Effects of pegaptanib sodium on retinal function in isolated perfused vertebrate retina

Current Eye Research

Volumn 35, Issue 3, 2010, Pages 248-254

  Lüke, Matthias ^a   Januschowski, Kai ^b   Tura, Aysegül ^a   Lüke, Julia ^a   Nassar, Khaled ^a   Lüke, Christoph ^c   Schneider, Toni ^c   Szurman, Peter ^b   Grisanti, Salvatore ^a   Bartz Schmidt, Karl Ulrich ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Electroretinogram; Exudative age related macular degeneration; Isolated perfused retina; Macugen; Pegaptanib sodium; Retinal biocompatibility

Indexed keywords

PEGAPTANIB; SILVER; SILVER CHLORIDE; VASCULOTROPIN;

A WAVE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B WAVE; CONTROLLED STUDY; COW; DRUG EFFECT; DRUG SAFETY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EYE TOXICITY; ISOLATED RETINA; NERVE CELL; NERVE CELL MEMBRANE POTENTIAL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA; TISSUE PERFUSION; VERTEBRATE;

ANGIOGENESIS INHIBITORS; ANIMALS; APTAMERS, NUCLEOTIDE; CATTLE; ELECTRORETINOGRAPHY; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950853420     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903503504     Document Type: Article

References (23)

1. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816 (Pubitemid 40051904)
2. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508-1521
3. Ishida S, Usui T, Yamashiro K, et al.VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-489 (Pubitemid 36976059)
4. Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroi dal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-167 (Pubitemid 27129479)
5. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934 (Pubitemid 26324159)
6. Pauleikhoff D. Neovascular age-related macular degeneration: Natural history and treatment outcomes. Retina 2005;25:1065-1084 (Pubitemid 44735105)
7. Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 2005;102:18902-18907 (Pubitemid 43049539)
8. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132
9. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451-1459 (Pubitemid 41541430)
10. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67 (Pubitemid 47339226)
11. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERI-1/2 and Akt pathways. J Neurosci 2006;26:12439-12446 (Pubitemid 44864508)
12. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: Promises and potential problems. JAMA 2005;293:1509-1513 (Pubitemid 40393297)
13. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-e15 (Pubitemid 44442453)
14. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-1611
15. Luke M, Weiergraber M, Brand C, et al. The isolated perfused bovine retina-A sensitive tool for pharmacological research on retinal function. Brain Res Brain Res Protoc 2005;16:27-36 (Pubitemid 41774068)
16. Hanawa I, Tateishi T. The effect of aspartate on the electroretinogram of the vertebrate retina. Experientia 1970;26:1311-1312
17. Luke C, Walter P, Bartz-Schmidt KU, et al.Effects of antiviral agents on retinal function in vertebrate retina. In: K Green (Ed.). Advances in Ocular Toxicology. New York: Plenum Press, 1997; pp. 107-112
18. Walter P, Luke C, Sickel W. Antibiotics and light responses in superfused bovine retina. Cell Moll Neurobiol 1999; 19:87-92 (Pubitemid 29102097)
19. Foy JW, Rittenhouse K, Modi M, et al. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J Ocul Pharmacol Ther 2007;23:452-466 (Pubitemid 350202486)
20. Lipski A, Bornfeld N, Jurklies B. Multifocal electroretinography in patients with exudative AMD and intravitreal treatment with pegaptanib sodium. Retina 2007; 27:864-872 (Pubitemid 47479381)
21. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290:H560-H576
22. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511 (Pubitemid 44620390)
23. Luke M, Warga M, Ziemssen F, et al.Tuebingen Bevacizumab Study Group. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90:1178-1182 (Pubitemid 44351153)